From the Physical Sciences, GlaxoWellcome Medicines
Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY,
the ¶ Department of Chemical Pathology, Southampton General
Hospital, Tremona Road, Southampton, Hampshire SO16 6YD, the
School of Pharmacy and Biomedical Sciences, University of
Portsmouth, White Swan Road, Portsmouth, Hampshire PO1 2DT, and the
** Department of Chemistry, University of Southampton, Highfield,
Southampton, Hampshire SO17 1BJ, United Kingdom
Received for publication, December 1, 2000
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We previously identified vitamin
B6 deficiency in a child presenting with seizures
whose primary diagnosis was the inherited disorder
hyperprolinemia type II. This is an unrecognized association, which was not explained by diet or medication. We hypothesized that
pyridoxal phosphate (vitamin B6 coenzyme) was de-activated by L- Vitamin B6 (pyridoxine and related compounds) is
distributed widely in food (1-2). Severe nutritional deficiency is not
common in humans (3) and has generally arisen in unusual circumstances. Most reports were in the early 1950s and described babies who presented
with seizures after being fed with processed milks lacking the vitamin
for over 2 months (4). Deficiency has also developed during treatment
with drugs that de-activate or antagonize the vitamin, causing
dermatitis, seizures, or neuropathy (2, 4-7). This analytical study
was prompted by finding vitamin B6 deficiency in a child
with hyperprolinemia type II (genetic classification McKusick 23591, Online Mendelian Inheritance in Man, available on the Web), a
rare inherited disorder due to lack of the enzyme 1-pyrroline-5-carboxylic acid, the
major intermediate that accumulates endogenously in hyperprolinemia
type II. The proposed interaction has now been investigated in
vitro with high resolution 1H nuclear magnetic
resonance spectroscopy and mass spectrometry at a pH of 7.4 and
temperature of 310 K. Three novel adducts were identified. These were
the result of a Claisen condensation (or Knoevenagel type of reaction)
of the activated C-4 carbon of the pyrroline ring with the
aldehyde carbon of pyridoxal phosphate. The structures of the adducts
were confirmed by a combination of high performance liquid
chromatography, nuclear magnetic resonance, and mass spectrometry. This
interaction has not been reported before. From preliminary
observations, pyrroline-5-carboxylic acid also condenses with other
aromatic and aliphatic aldehydes and ketones, and this may be a
previously unsuspected generic addition reaction.
Pyrroline-5-carboxylic acid is thus found to be a unique endogenous
vitamin antagonist. Vitamin B6 de-activation may contribute
to seizures in hyperprolinemia type II, which are so far unexplained,
but they may be preventable with long term vitamin B6 supplementation.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1-pyrroline-5-carboxylate dehydrogenase (EC 1.5.1.12)
(8) (Fig. 1). This association has not
been reported before.
View larger version (39K):
[in a new window]
Fig. 1.
The catabolism of L-proline.
The asterisk indicates the enzyme deficiency in
hyperprolinemia type II.
Full clinical details of the case and diagnostic biochemistry have been reported previously (9). In brief, a previously healthy girl presented at 20 months of age with prolonged seizures and depressed conscious level in association with pneumonia. She was well nourished and usually had a normal mixed diet. Abnormalities of plasma and urine biochemistry were diagnostic of hyperprolinemia type II (8). Plasma proline was 2690 µM (reference range 90-280 µM) and has remained high since (2290-2955 µM, six observations over 2 years). She recovered slowly over 5 days and was then healthy, except for a severe diaper rash during convalescence. Xanthurenic acid was found in her urine organic acid profile at presentation.
We have not seen this tryptophan metabolite in other children's urine, and it indicated the possibility of vitamin B6 deficiency (1, 2, 4, 5). We confirmed this by finding marginally low plasma pyridoxal phosphate concentrations (23.5 and 22.7 µM; reference range 24.3-81.0 µM) and barely detectable pyridoxic acid (1.0 and 2.7 µM, reference range 10.9-27.3 µM) in her plasma on two occasions when she was well (3 and 8 months after her illness) and a grossly abnormal response to tryptophan loading at 8 months after presentation (9).
The deficiency was not nutritional or due to ingestion of antagonistic
drugs. We therefore proposed that the vitamin was de-activated by an interaction between pyridoxal phosphate
(PP)1 (Structure T1), the
active coenzyme form of vitamin B6 (the keto [1k]
tautomer), and L-1-pyrroline-5-carboxylic
acid (P5C) (Structure T2), the
intermediate which accumulates in hyperprolinemia type
II. (Structures T1 and T2).
|
|
There was some foundation for this, because a chemical test for P5C is based on its reaction with 2-aminobenzaldehyde (10). This reagent, like pyridoxal phosphate, is an aromatic aldehyde. We have now investigated the proposed interaction in vitro using mass spectrometry (MS) and high resolution 1H nuclear magnetic resonance (NMR) spectroscopy.
Preliminary NMR and high performance liquid chromatography-mass
spectrometry (HPLC-MS) studies confirmed a reaction between PP and P5C
co-incubated in aqueous solution at physiological pH (7.4) and
temperature (310 K). Three adducts were produced, which we have
characterized and found to be novel. They result from a Claisen
condensation (or Knoevenagel type of reaction) involving the pyridoxal
phosphate carbonyl group and the activated C-4 carbon of the pyrroline
ring. This reaction has not been reported before. The most common type
of in vivo enzymatic reaction of PP is in transamination,
the transfer of an -amino group of an amino acid to the
-carbon
atom of an
-keto acid (5, 11). These reactions are reversible and
involve the formation of Schiff bases as intermediates. Therefore, P5C
is a unique endogenous pyridoxal phosphate antagonist. If this
condensation occurs in vivo, as we propose, individuals with
hyperprolinemia type II would have an increased vitamin B6 requirement and be at risk of symptomatic deficiency. In preliminary observations we find that P5C also reacts with a range of aliphatic aldehydes and ketones and benzaldehyde at physiological pH. This condensation may be a newly recognized general reaction with activated carbonyls.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials--
DL-1-Pyrroline-5-carboxylic
acid, 2,4-dinitrophenylhydrazine hydrochloride double salt,
pyridoxal-5-phosphate, pyridoxamine dihydrochloride, 4-pyridoxic
acid, pyridoxine, and pyridoxal hydrochloride were from Sigma, and
acetophenone (99% pure), benzaldehyde, and aliphatic aldehydes were
from Aldrich (Sigma-Aldrich Company Ltd., Poole, UK). Deuterium oxide
(D2O), deuterium chloride (DCl), and sodium deuteroxide
(NaOD) were from Goss Scientific Instruments Ltd., Great Baddow, UK.
Sodium-3-trimethylsilyl-1-[2,2,3,3-2H4]propionate
(TSP) was from Fluorochem Ltd., Old Glossop, Derbyshire, UK, and
diethyl ether (Analar) from BDH, Poole, Dorset, UK. Glassware for P5C
preparation was acid-washed.
Preparation of P5C and Pyridoxal Phosphate Co-incubates-- The P5C was prepared from its 2,4-dinitrophenylhydrazine hydrochloride double salt, using a method based on that of Mezl and Knox (12) but modified by using a more concentrated starting solution of the hydrazine and a diethyl ether wash instead of toluene to remove excess acetophenone. Preparations made according to the published method were found by NMR to be contaminated with toluene and acetophenone, and P5C was polymerized. Thus a slightly modified method was adopted. To 40 mg of the hydrazine in a glass tube were added 2.0 ml of 0.25 M DCl and 8 ml (0.2 ml/mg hydrazine) of acetophenone. The mixture was shaken on a roller mixer for 30 min in a cold room at 4 °C. After centrifugation, the lower aqueous layer was transferred to a clean tube and washed with ~8 ml of diethyl ether five times to remove acetophenone. Ether was removed from the aqueous extract by evaporation under nitrogen at room temperature. After adjusting the pH to 7.4 with NaOD, the extract was stored at 4 °C. NMR confirmed P5C to be present, with no evidence of polymerization or contamination with acetophenone. This is the first report of the NMR spectrum of P5C (shown in Fig. 3B). Contrary to expectation (12) we found that P5C was reasonably stable under these conditions, with no evidence of polymerization after 4 weeks of storage at room temperature. Different batches showed varying rates of degradation, and after 3 months each batch had degraded by ~50-70% to a complex mix of monomeric substances. Pyridoxal phosphate (PP) (5 mg/ml in D2O) was adjusted to pH 7.4 with NaOD, protected from light, and stored at 4 °C. NMR (see Fig. 3A) confirmed the purity of the preparation and the 4:1 ratio of the keto to enol forms.
Incubates of P5C and PP were prepared in two ways. In the earlier experiments, 250 µl of stock P5C was added to 5 mg of PP (solid) in a vial, the pH was adjusted immediately to 7.4 with NaOD, D2O was added to a volume of 1.5 ml, and the pH was readjusted to 7.4. In later experiments, aliquots of stock solutions of P5C and PP, both prepared at pH 7.4, were mixed and diluted appropriately with D2O, and the pH was readjusted to 7.4. The method of preparation did not influence the products of co-incubation.
After incubation at 310 K for 24 h,
the mixture was analyzed, initially using HPLC-MS (Fig. 2) and then NMR
(Fig. 3C, around 36 h
after mixing). The solution was found to be reacting slowly at ambient
temperature, and the reaction was monitored by 1H NMR over
a period of 12 days. The mixture was then characterized by MS and
1H NMR and heteronuclear NMR, including
1H-13C correlation experiments HMQC and HMBC at
14.1 tesla (T) and 17.6 T. In addition, diffusion (13) and gradient nOe
experiments (14) were employed to distinguish the various components in the mixture. The structures were further confirmed by HPLC-NMR-MS.
|
|
HPLC-MS-- The mass spectra were obtained under positive and negative ionization conditions on a Micromass Platform II electrospray HPLC-MS system. The HPLC was carried out on an HP1100 (Hewlett Packard) system using a reverse phase C18 column (Phenomenex 100 × 2.0 mm) at ambient temperature. The eluents were water and acetonitrile with 0.1% formic acid added as an ion-pairing agent. An 8-min gradient from 100% water to 100% acetonitrile was employed, and the fractions were observed using a UV diode array detector followed by MS.
NMR-- Experiments were carried out at 750.3 MHz (1H) and 188.7 MHz (13C) on a Varian INOVA 750 (17.6 T) spectrometer and at 600.13 MHz (1H), 150.9 MHz (13C), and 242.9 MHz (31P) on a Bruker DRX600 (14.1 T) spectrometer. To 500 µl of each sample in a 5-mm NMR tube, 10 µl (10 µg) of 0.1% w/v TSP in D2O was added to enable accurate quantification and act as an internal shift reference. The one-dimensional 1H NMR experiments were carried out under conditions of full relaxation and good digitization to enable reasonable integration for quantification. The 90° pulses used were calibrated after tuning and matching the rf for each sample at the temperatures for which different measurements were taken.
Typically 65,536 data points were acquired over a 16.02-ppm (9614 Hz at
600 MHz) spectral width or 131,072 data points over 16.0 ppm (12,001 Hz
at 750 MHz) using a noesypresat (15) solvent suppression pulse
sequence. A mixing time of 100 ms, together with 3 s of
presaturation and an acquisition time of 3.4 s at 600 MHz or
5.3 s at 750 MHz, was employed. The gradient nOe experiments were
done at 750 and 600 MHz using the same respective data tables as above,
with mix times of 0.8-1 s and gradient ratios of 35:5:3:2:1 and from
2000 to 8000 transients per experiment. The diffusion experiments (Fig.
4) were acquired as above at 750 MHz with
the diffusion time fixed at 0.5 s. The gradient strength was
ramped successively from 0.5 to 30.5 gauss/cm in increments of 2 gauss with 16 experiments each of 64 transients acquired with a repetition time of 5 s per transient.
|
Two-dimensional experiments TOCSY, HMQC, and HMBC were run at 750 MHz and 310 K (nominal, actual temperature was 311.4 K) in phase-sensitive mode, typically 2048 (or 4096 for HMBC) data points acquired over a 13-ppm spectral width in F2 (and F1 for the TOCSY homonuclear experiment), the proton dimension, and 200 ppm in F1 for the carbon dimension. The TOCSY experiment was carried out with 32 transients for each of 256 increments using a spin lock period of 60 ms and a relaxation delay of 1.5 s, during which the HOD signal was pre-saturated to reduce the dynamic range. A total of 256 transients at a pulse repetition rate of 0.5 s per scan for each of 128 increments in the HMQC, and 440 transients (pulse repetition rate equal to 1.5 s) for 256 increments in the HMBC experiment were employed. Globally optimized alternating-phase rectangular decoupling of the carbon frequencies was employed in the HMQC experiment. Cosine window functions were used in the F2 (acquisition dimension) and linear prediction to 1024 complex data points (coefficients optimized for each experiment) with no window function applied in the F1 dimension, prior to Fourier transformation.
Phosphorus Spectra-- The phosphorus spectra were acquired at 242.9 MHz (14.1 T) with and without proton decoupling {1H} using 65,536 data points over 50 ppm with 640 transients for both experiments, employing 90° pulses at a pulse repetition time of 4.7 s. An external reference of phosphoric acid was used for calibration and set to 0 ppm. A line broadening of 1 Hz was used in the exponential multiplication window function to increase the apparent signal to noise prior to Fourier transformation.
Carbon Spectra--
The carbon spectra were acquired with
Waltz-16 (1
|
HPLC-NMR-- With gradient elution, HPLC-NMR was carried out using a Bruker LC-22 HPLC system. The mobile phase was pumped at 1 ml/min through a C18 reverse phase column (Phenomenex 250 × 4.6 mm) at 25 °C. The eluents were D2O and CH3CN (ACN) each with 0.05% trifluoroacetic acid added, starting with 100% D2O decreasing to 60% D2O and 40% ACN over 25 min, followed by a 2-min 100% ACN purge flush before returning to 100% D2O. The eluting fractions were detected by UV (Bischoff Lambda 1000) at 254 nm, and the absorption was used as a delayed trigger to stop the pump when the fraction had flowed into the NMR probe cell. The 1H NMR at 600 MHz was measured while the flow was stopped.
The pulse sequence was noesypresat with double-solvent suppression and
ACN 13C satellite decoupling. A selective-shaped rf pulse
was employed, with frequency adjusted to the ACN at the center of the
spectrum (2 ppm also used as internal reference) and to the residual
HOD signal, which reduced its shift value with increasing ACN
concentration during the gradient elution. Shape selective gradient
shimming of the ACN signal was used to maximize the magnetic field
homogeneity. The number of transients taken varied from 128 to 1024 for
the different fractions, prior to continuing the HPLC pump and moving on to the next peak in the UV. The number of scans depended upon the
fraction's concentration and the signal-to-noise ratio achieved between 5 and 11 ppm. Each fraction was collected post-NMR using a Foxy
Junior fraction collector and was then run on a Micromass Platform
Q-TOF in positive ion electron impact conditions for accurate mass
measurement. Erythromycin was co-injected, and the ion at
m/z = 734.4690 used as the lock reference mass.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The initial analysis was by MS of the mixture, arising from a 24-h
incubation at 310 K of 1 ml of P5C and 1 ml of PP solution (Fig. 2).
Three new quasimolecular ions (M H)
were observed
at m/z = 297, 341, and 359 Da by negative
ion electrospray, in addition to the expected quasimolecular ions for
P5C at m/z = 112 and PP at
m/z = 246 Da. The initial 1H NMR
spectrum at 600 MHz (Fig. 3C, after 36 h of reaction)
of the same solution at 298 K showed several products in addition to
the two starting components.
In an attempt to analyze these components in situ, while the reaction was still ensuing, a series of diffusion (13) experiments were conducted at 750 MHz for maximum shift dispersion. The mixture was partially resolved into its component parts, termed Diffusion Ordered SpectroscopY (DOSY) (16, 17) as illustrated in Fig. 4. The technique relies upon the individual species having different diffusion coefficients, which often vary with the size of the molecule. Hence, for neutral compounds, a separation of each compound's spectrum along the diffusion axis occurs with increasing molecular mass. However, if there is molecular association of any kind, the diffusion coefficient of the associated components will change and the above progression no longer holds. The products were obviously the result of reaction of P5C and PP, because signals with similar shifts and couplings were observed. The question was, what structures did they have?
The lack of any additional aldehyde proton signals around
9.5-10.5 ppm indicated that reaction had occurred at that site on the
PP. The appearance of a finely coupled triplet of doublets at 6.93 suggested an olefinic proton with three remote coupling partners. A
series of one-dimensional TOCSY experiments established that these were
a pair of double, double doublets (ddd) at
2.36 and
2.75 and a
finely coupled doublet at
8.09. The former were a geminal methylene
pair and the latter an olefinic proton
to a hetero-atom, similar to
H5 in P5C. These signals, when carefully integrated and compared with
the signal at
6.93, were present at equimolar equivalents to one another.
The diffusion spectra revealed that a significant set of signals
was hidden under the water signal at 4.77. The sample was therefore
heated to 310 K, causing the water signal to shift to a higher field
and the multiplets thus became observable in the one-dimensional
noesypresat spectrum. They integrated for a total of three protons when
compared with the new doublet at
8.09.
At this point a series of heteronuclear experiments were
measured, first on 31P to establish the presence of the
phosphate group. Three clearly distinguishable triplets were observed,
the largest at the lowest field 5.19 was attributed to the
unreacted PP. The other two triplets at
5.02 and
5.08 were
clearly new phosphate-containing molecules. Other signals were present
but were overlapped by the major and minor components or at too low a
concentration to be observed at the signal-to-noise level achieved.
The next step involved acquisition of an HMQC and HMBC
1H-13C correlated set of two-dimensional
spectra (Fig. 5). The identity of the reaction products was deduced by
combination of the two data sets. The coupled network of five carbons
connected to the geminal methylene pair corroborated the earlier
one-dimensional evidence and confirmed the olefinic functionality. The
possibilities for the reaction products were thus narrowed down to one
site of reaction on the P5C, namely the C-4 carbon. The other
possibilities arising from either isomers of P5C or the ring opened
form DL-glutamic--semialdehyde (the latter would involve
addition of the amine to the aldehyde of PP to form a Schiff base) were
all excluded on the basis of the coupling network observed from the
TOCSY and HMBC experiments.
|
The proposed new Structures 3a and 3b would have
resulted from an addition of the C-4 carbon to the aldehyde of PP,
reminiscent of the Knoevenagel reaction, with the imine function of P5C
behaving like the carbonyl in the more usual ketone-aldehyde reaction. Following the condensation, elimination of water formed an olefin with
two possible stereoisomers, one of which turned out to be the major
product with a molecular mass of 342 Da. Distinction between these
isomers was achieved using double-pulse field gradient nOe (14)
experiments as shown in Fig.
6B. Selective inversion of the
resonance at 6.93 resulted in a positive enhancement of the signals
at
8.09 and
4.76, thus proving that the major product isomer
had the configuration as shown in Structure 3a.
|
The other new components observed in the spectra were characterized in
the same way. The precursor to Structures 3a and 3b was Structure T4 and
was steadily converted to the olefins (Structure T3) on standing.
Structure 4's molecular mass was 360 Da.
|
The spectrum in Fig. 3C was not definitive, because
there are three chiral centers, and the eight diastereoisomers
are paired into four NMR distinguishable structures. The spectrum
obtained by HPLC-NMR established the presence of two
NMR-distinguishable structures. The multiplets at 4.84 and
4.91 and their coupled partners from the one-dimensional TOCSY at
2.11, ~
2.3 (obscured by methyls), and
7.99 suggested the presence
of two of the diastereomeric structures represented by Structure T4. We
have found no evidence of the formation of the remaining two possible
diastereoisomers, possibly because these are also transient products
present at even lower concentrations than their isomers. From the NMR
data obtained, we are unable to assign the stereochemistry of the
observed diastereoisomers.
The third (minor) component consisted of the compounds with
m/z of 297. Their identities were more difficult
to prove, because they were present at low concentration. However, the
HPLC-NMR-MS resolved them satisfactorily and confirmed their structures
that of Structure T5.
|
The key information was the absence of any signal between 4 and 5 ppm and the presence of two mutually coupled pairs of methylene groups. Two isomeric forms of this compound were observed, the E and Z forms. However, owing to the small quantity (~2 µg) present in the mixture, it was not feasible to prove which was the major isomer. The observed chemical shifts and coupling constants for the various components identified in the mixture at 310 K after 12 days of reaction are listed in Table I.
|
Concentrations of compounds in the reaction mixture after 36 h of incubation were PP 6.9 mM, P5C 4.6 mM, and the three products 1.14 mM (Structure 3a), 0.23 mM (Structure 3b), and 1.50 mM (Structure T4). To discover whether the same reactions occur at lower concentrations (closer to those expected in vivo), aliquots of each stock solution were diluted 10-fold with D2O, mixed, and again incubated at 310 K. This reaction was monitored by 1H NMR and MS and confirmed that products were formed with similar chemical shifts in the 1H NMR and quasimolecular ions of the same mass as those observed in the reaction at the higher concentration.
Interaction of P5C with Other Aldehydes and Ketones--
We
incubated P5C with a range of aldehydes and ketones and successfully
formed condensation products with formaldehyde, acetaldehyde, propionaldehyde, butyraldehyde, valeraldehyde, benzaldehyde, pyruvic aldehyde, glyoxylic acid, pyruvic acid (methyl glyoxylic acid), acetoacetic acid, 2-oxobutyric acid, and oxaloacetic acid. New products
were confirmed by gas chromatography-MS (GC-MS) of their trimethylsilyl
(tms) derivatives. The first seven of these (all aldehydes) had
products with the molecular mass predicted for di-tms derivatives. The
second group of four acids had tri-tms, and the last, oxaloacetic acid,
had a tetra-tms derivative of the corresponding P5C/carbonyl adduct
(comparable with Structure T4 for P5C/PP). The key product was the
acetoacetic acid/P5C adduct, molecular mass 432 Da, for the tri-tms
derivative. We found the latter in the first urine sample collected
from the child at the time of her acute illness. This specimen showed
moderate ketonuria (4 mM) upon stick testing. The
characterization of this adduct and others, will be the subject of a
separate publication.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Vitamin B6 deficiency was an unexpected, incidental, finding in this child, whose primary problem is the inherited disorder hyperprolinemia type II. The association has not been reported before. There was no question of nutritional deficiency, and the explanation, therefore, had to be antagonism or de-activation of the vitamin. A range of antagonists is known (5, 18, 19), and these have been categorized into three groups (19). First, structural analogues of vitamin B6 (for example, 4-deoxypyridoxine (20)); second, substances that are analogues of natural substrates for vitamin B6-dependent enzymes and are converted to intermediates, which bind to the enzymes irreversibly (19); and third, carbonyl reactive reagents that react with the aldehyde group of PP and thereby block its coenzyme activity. These agents include hydrazines, which form hydrazones (examples are 1-amino-D-proline in linseed oil and several drugs, including the anti-tuberculous agent isoniazid, carbidopa, phenelzine, and hydralazine), substituted hydroxylamines, which form oximes (for example, D-cycloserine and L-canaline), and sulfydryl compounds, including L-penicillamine (5, 18, 19).
Because the child was not receiving any vitamin antagonists as
medication, the alternative was that an endogenous compound was
responsible. This was likely to be an intermediate that accumulates as
a result of her primary inherited disorder. Biochemical conversions of
amino acids by PP-dependent enzymes involve formation of a Schiff base between the amino acid and PP (5, 21). Because proline is an imino acid that does not react with the
carbonyl group of PP (8, 21), it was unlikely that this was the
de-activator, and we confirmed its non-reactivity by GC-MS and HPLC-MS.
The alternative was P5C, which is in equilibrium with
L-glutamic--semialdehyde (Fig. 1). One possibility
was formation of a Schiff base between the C-4 amino group of
pyridoxamine and the carbonyl group of the semialdehyde. However, at
physiological pH, the equilibrium would favor P5C, which would be the
predominant form of the intermediate, and, in preliminary studies, we
found no evidence of interaction between P5C and pyridoxamine.
Pyridoxine and 4-pyridoxic acid were also inactive. Thus it was
probable that, as for other reported vitamin B6
antagonists, the C-4 carbonyl group of PP was involved in the
proposed interaction, and we confirmed this for PP in vitro at physiological pH and temperature. Studies with pyridoxal were inconclusive, because its aldehyde group was de-activated by formation of a hemi-acetal (22) in our experimental conditions. However, this
would not preclude the possibility of analogous reaction in
vivo for pyridoxal.
The P5C/PP conjugates that we synthesized and characterized have not
been reported before. They are neither hydrazones nor oximes and
represent a new class of vitamin B6 adducts. Covalent bonding with the PP aldehyde group would de-activate the vitamin. The
mechanism of reaction has not been proven. However, based upon chemical
knowledge of the system, we propose an addition of a proline-derived
species to the aldehyde followed by a base-catalyzed elimination as
shown in Scheme 1, to be the most likely
sequence. We found definitive evidence for deuteration of P5C at
C-4 in D2O, in that both methylene protons at C-4 of P5C
disappeared in the 12-day mixture. In addition, the residual C-3
methylene protons show a greatly simplified apparent coupling pattern,
as a result of the deuteron substitution for their vicinal partners (see the one-dimensional reference spectrum in Fig. 5).
|
Our preliminary observations that P5C also reacts with other aliphatic and aromatic aldehydes and ketones at physiological (i.e. slightly alkaline) pH suggest that this condensation may be a generic reaction of activated carbonyl compounds. Some of these interactions, for example P5C with acetoacetic acid, occur in vivo in hyperprolinemia type II.
At present, the evidence that the P5C/PP interaction demonstrated in vitro occurs in this child in vivo is circumstantial: namely, that she had vitamin B6 deficiency without any apparent explanation other than life-long exposure to abnormally high concentrations of P5C. So far we have not been able to demonstrate any of the three new adducts in her plasma or urine in free form or as glucuronide, sulfate, or glycine conjugates by GC-MS (as tms derivatives) or by NMR. The adducts may be too unstable for extraction and derivatization for GC-MS analysis and the concentrations too low for NMR.
In vitro we demonstrated PP/P5C interaction at a P5C
concentration of 0.46 mM. This is much higher than plasma
P5C concentrations found normally (0.2-2 µM) and in
hyperprolinemia type II (10-40 times normal) (8, 23, 24). P5C,
however, is an intracellular metabolite produced in liver, kidney, and
brain by the mitochondrial enzyme proline oxidase (no EC number
assigned) (8). Normally it is then converted to glutamic acid by
1-pyrroline-5-carboxylic acid dehydrogenase in the
mitochondrial matrix (Fig. 1) (25-27). Some also diffuses into the
cytoplasm, where it is reduced back to proline by P5C reductase (EC
1.5.1.2) generating NADP+ from NADPH and driving the
pentose phosphate shunt (8, 28). Deficiency of P5C dehydrogenase in
hyperprolinemia type II leads to a considerable increase in the
cytoplasmic flux of P5C to proline, as evidenced by the very high
proline concentrations observed (8) (2.29-2.96 mM).
Because there is a large rapidly exchanging pool of vitamin
B6 in the liver (29) with most PP located in the cytosol
(30), concentrations of P5C and PP might be high enough for interaction
in hyperprolinemia type II. We have shown in vitro that the
P5C/PP adducts form at pH 7.2, the usual cytosolic pH level (31).
Consumption of PP in such a reaction would lead to reduced production
of 4-pyridoxic acid, the principal degradation product of vitamin
B6 (29, 32). This could explain the unrecordably low
concentrations of 4-pyridoxic acid in the plasma of this child.
Hyperprolinemia type II presents typically with seizures in early
childhood, precipitated by infection, as in this case. Rashes have also
been reported (8, 24, 33). This child has some speech delay and others
have had developmental problems (34, 35), but this is not a consistent
finding (24). Some affected children detected through family studies
have not had seizures, and in a large Irish kindred they did not occur
in adult life (24). The explanation for the seizures and their variable
occurrence is unknown. One possibility is linkage between the
hyperprolinemia type II gene and an unrelated gene, which causes
seizures (24), this seems unlikely. The gene mutation has not been
identified yet in this child, but it was shown not to be the one in the
Irish kindred whose affected members had a similar clinical
presentation (36). It is more likely that biochemical disturbances
resulting from the enzyme deficiency are responsible. Proposed
mechanisms have been accumulation of proline, a neuromodulator (8, 24), and overactivity of the pentose phosphate pathway (28, 37). We believe
that acquired vitamin B6 deficiency was implicated in the
seizures in this child and perhaps in her rash. Changes in her
electroencephalogram were consistent with this (9). Seizures and rash
are features of severe vitamin B6 deficiency (2, 4, 5) and
intractable seizures occur in pyridoxine dependence, a rare inherited
disorder of infancy (38, 39). Altered turnover of the neurotransmitters
-aminobutyric acid and glutamic acid has been implicated in these
disorders (5, 38, 40). Acquired vitamin B6 deficiency
combined with depletion of glutamic acid because of the inherited
deficiency of P5C dehydrogenase (see Fig. 1) may increase the risk of
seizures in hyperprolinemia type II.
Our ongoing studies, however, indicate that P5C also forms adducts with other biologically important aldehydes and ketones. These include pyruvic acid, oxaloacetic acid, and acetoacetic acid, each of which are central intermediates in metabolism. We have shown P5C/acetoacetic acid adducts unequivocally in this child's urine and thereby demonstrated their production in vivo. With improved analytical sensitivity, we anticipate that other conjugates will be detected. An accumulation of P5C may, therefore, have previously unsuspected effects on body biochemistry. One or more of these adducts may also be implicated in seizures.
Our studies have demonstrated a novel interaction between P5C and PP,
which would de-activate the vitamin. If this occurs in vivo,
as we believe, P5C represents a unique endogenous vitamin B
6 antagonist. It remains to be seen whether other
individuals with hyperprolinemia type II are also vitamin
B6 deficient. We advise that affected individuals have
plasma PP and 4-pyridoxic acid measured, because correction of a
deficiency may help to prevent seizures. It would also be important to
search for other biologically important P5C conjugates in their blood
and urine.
![]() |
ACKNOWLEDGEMENTS |
---|
We are grateful to GlaxoWellcome for access to analytical facilities, to Prof. Trevor Crabb (Emeritus), University of Portsmouth, UK, for advice, Dr. Lesley Canfield, University of Portsmouth, UK, for preliminary NMR analyses, Prof. David Valle, The Johns Hopkins University School of Medicine, Baltimore, MD, for DNA analysis, and Dr. Sheila Peters, Consultant Paediatrician, St. Mary's Hospital, Portsmouth, UK, for assistance with investigation of her patient.
![]() |
FOOTNOTES |
---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) .
§ To whom correspondence should be addressed: Analytical Technologies, GlaxoWellcome Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, UK. Tel.: 44-0-1438-768026; Fax: 44-0-1438-763352; E-mail: rdf17079@glaxowellcome.co.uk.
Published, JBC Papers in Press, December 29, 2000, DOI 10.1074/jbc.M010860200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are:
PP, pyridoxal
phosphate;
P5C, L-1-pyrroline-5-carboxylic
acid;
MS, mass spectrometry;
GC, gas chromatography;
HPLC, high
performance liquid chromatography;
TSP, sodium-3-trimethylsilyl-1-[2,2,3,3-2H4]propionate;
ACN, CH3CN;
tms, trimethylsilyl;
DOSY, diffusion ordered
spectroscopy;
nOe, nuclear Overhaüser enhancement;
HMQC, heteronuclear multiple-quantum correlation;
HMBC, heteronuclear
multiple-bond correlation;
TOCSY, total correlation spectroscopy;
rf, radio frequency, noesypresat, nuclear Overhaüser enhancement
spectroscopy pre-saturation.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | György, P. (1968) in The Vitamins (Sebrell, W. H. , and Harris, R. S., eds), 2nd Ed., Vol. II , pp. 90-104, Academic Press, Inc., New York |
2. | McCoy, E. E. (1986) in Coenzymes and Cofactors Vol. I Vitamin B6. Pyridoxal Phosphate. Part B (Dolphin, D. , Poulson, R. , and Avramovic, O., eds) , pp. 573-600, John Wiley and Sons, Inc., New York |
3. | Bates, C. J. (1997) Ann. Clin. Biochem. 34, 599-626[Medline] [Order article via Infotrieve] |
4. | Tryfiates, G. P. (1986) in Coenzymes and Cofactors Vol. I Vitamin B6. Pyridoxal Phosphate. Part B (Dolphin, D. , Poulson, R. , and Avramovic, O., eds) , pp. 421-447, John Wiley and Sons, Inc., New York |
5. | Holtz, P., and Palm, D. (1964) Pharmacol. Rev. 16, 113-178[Medline] [Order article via Infotrieve] |
6. | Sauberlich, H. E. (1968) in The Vitamins (Sebrell, W. H. , and Harris, R. S., eds), 2nd Ed., Vol. II , pp. 33-44, Academic Press, Inc., New York |
7. | Alvarez, F. G., and Guntupalli, K. K. (1995) Intensive Care Med. 21, 641-644[Medline] [Order article via Infotrieve] |
8. | Phang, J. M., Yeh, G. C., and Scriver, C. R. (1995) in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R. , Beaudet, A. L. , Sly, W. S. , and Valle, D., eds) , pp. 1125-1146, McGraw-Hill, Inc., New York |
9. |
Walker, V.,
Mills, G. A.,
Peters, S. A.,
and Merton, W. L.
(2000)
Arch. Dis. Child.
82,
236-237 |
10. | Vogel, H. J., and Davis, B. D. (1952) J. Am. Chem. Soc. 74, 109-122 |
11. | Snell, E. E., Braunstein, A. E., Severin, E. S., and Torchinsky, Yu. M. (eds) (1968) Pyridoxal Catalysis: Enzymes and Model Systems , pp. 770-782, Interscience, New York |
12. | Mezl, V. A., and Knox, W. E. (1976) Anal. Biochem. 74, 430-434[Medline] [Order article via Infotrieve] |
13. | Stejskal, E. O., and Tanner, J. E. (1965) J. Chem. Phys. 42, 288-292 |
14. | Stott, K., Keeler, J., Van, Q. N., and Shaka, A. J. (1997) J. Magn. Reson. 125, 302-324[CrossRef] |
15. | Nicholson, J. K., Foxall, P. J. D., Spraul, M., Farrant, R. D., and Lindon, J. C. (1995) Anal. Chem. 67, 793-811[Medline] [Order article via Infotrieve] |
16. | Gibbs, S. J., and Johnson, C. S., Jr. (1991) J. Magn. Reson. 93, 395-402 |
17. | Barjat, H., Morris, G. A., Smart, S., Swanson, A. G., and Williams, S. C. R. (1995) J. Magn. Reson. Ser. B 108, 170-172[CrossRef] |
18. | Klosterman, H. J. (1979) Methods Enzymol. 72, 483-495 |
19. | Klosterman, H. J. (1986) in Coenzymes and Cofactors Vol. I Vitamin B6. Pyridoxal Phosphate. Part A (Dolphin, D. , Poulson, R. , and Avramovic, O., eds) , pp. 392-415, John Wiley and Sons, Inc., New York |
20. | Coburn, S. P., Mahuren, J. D., Schaltenbrand, W. E., Wostmann, B. S., and Madsen, D. (1981) J. Nutr. 111, 391-398[Medline] [Order article via Infotrieve] |
21. | Stryer, L. (1988) Biochemistry, 2nd Ed. , pp. 496-499, W. H. Freeman and Company, New York |
22. | Richter, W., Vecchi, M., Vetter, W., and Walther, W. (1967) Helv. Chim. Acta 2, 364-376 |
23. | Fleming, G. A., Hagedorn, C. H., Granger, A. S., and Phang, J. M. (1984) Metabolism 33, 739-742[Medline] [Order article via Infotrieve] |
24. | Flynn, M. P., Martin, M. C., Moore, P. T., Stafford, J. A., Fleming, G. A., and Phang, J. M. (1989) Arch. Dis. Child. 64, 1699-1707[Abstract] |
25. | Strecker, H. J. (1960) J. Biol. Chem. 235, 3218-3223 |
26. |
Forte-McRobbie, C. M.,
Pietruszko, R.,
and Purifican, T.
(1986)
J. Biol. Chem.
261,
2154-2163 |
27. |
Small, W. C.,
and Jones, M. E.
(1990)
J. Biol. Chem.
265,
18668-18672 |
28. | Hagedorn, C. H., and Phang, J. M. (1986) Arch. Biochem. Biophys. 248, 166-174[Medline] [Order article via Infotrieve] |
29. | Coburn, S. P. (1996) Adv. Food Nutr. Res. 40, 107-132[Medline] [Order article via Infotrieve] |
30. | Bosron, W. F., Veitch, R. L., Lumeng, L., and Li, T.-K. (1978) J. Biol. Chem. 253, 1488-1492[Medline] [Order article via Infotrieve] |
31. | Darnell, J., Lodish, H., and Baltimore, D. (1986) Molecular Cell Biology , p. 32, Scientific American Books, New York |
32. | Ink, S. L., and Henderson, L. M. (1984) Ann. Rev. Nutr. 4, 455-470[CrossRef][Medline] [Order article via Infotrieve] |
33. | Similä, S. (1970) Ann. Clin. Res. 2, 143-150 |
34. | Emery, F. A., Goldie, L., and Stern, J. (1968) J. Ment. Defic. Res. 12, 187-195[Medline] [Order article via Infotrieve] |
35. | Wajner, M., Wannmacher, C. M. D., and Purkiss, P. (1990) Clin. Genet. 37, 485-489[Medline] [Order article via Infotrieve] |
36. |
Geraghty, M. T.,
Vaughn, D.,
Nicholson, A. J.,
Lin, W.-W.,
Jimenez- Sanchez, G.,
Obie, C.,
Flynn, M. P.,
Valle, D.,
and Hu, C. A.
(1998)
Hum. Mol. Genet.
7,
1411-1415 |
37. |
Yeh, G. C.,
and Phang, J. M.
(1988)
J. Biol. Chem.
263,
13083-13089 |
38. | Minns, R. (1980) Dev. Med. Child Neurol. 22, 795-799[Medline] [Order article via Infotrieve] |
39. |
Nabbout, R.,
Soufflet, C.,
Plouin, P.,
and Dulac, O.
(1999)
Arch. Dis. Child. Fetal Neonatal Ed.
81,
F125-F129 |
40. | Ebadi, M. (1986) in Coenzymes and Cofactors Vol. I Vitamin B6. Pyridoxal Phosphate. Part B (Dolphin, D. , Poulson, R. , and Avramovic, O., eds) , pp. 449-476, John Wiley and Sons, Inc., New York |